Trial Profile
A phase 1, open-label, single-center, randomized,crossover trial assessing the pharmacokinetics and safety of SYM-1219 in healthy women under different administration conditions.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jul 2018
Price :
$35
*
At a glance
- Drugs Secnidazole (Primary)
- Indications Bacterial vaginosis
- Focus Adverse reactions; Pharmacokinetics
- 23 Jul 2018 New trial record
- 01 Jul 2018 Results published in the Clinical Pharmacology in Drug Development